Skip to main content

Table 1 Patients’ characteristics at baseline

From: The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study

Characteristics

n (%)

 

(n = 13,559)

Age, in years, median (IQR)

34.6 (28.4–41.8)

Male

9937 (73.3)

Immigrant

1667 (12.3)

Intravenous drug use

4799 (35.4)

HBV/HCV co-infection

5890 (43.4)

HIV-RNA viral load undetectable

3082 (25.8)

ART

4532 (33.4)

CD4 cell count, median (IQR)

378 (214–571)

 0–49

611 (5.1)

 50–99

633 (5.3)

 100–199

1507 (12.56)

 200–349

2747 (22.9)

 350–499

2577 (21.5)

 ≥500

3932 (32.8)

CD4/CD8, median (IQR)

0.37 (0.20–0.61)

 <0.3

2215 (39.7)

 0.3–0.45

1119 (20.1)

 ≥0.45

2244 (40.2)

Lymphocytes, median (IQR)

1856 (1361–2390)

Neutrophils, median (IQR)

2694 (2000–3619)

Platelets, median (IQR)

210,999 (166,000–260,000)

NLR, median (IQR)

1.47 (1.03–2.17)

PLR, median (IQR)

109.9 (79.6–155.3)

  1. Missing values: Immigrant 81 (0.6 %); HIV-RNA viral load undetectable 1609 (11.9 %), CD4 cell count 1552 (11.5 %), CD4/CD8 7981 (58.9 %), Lymphocytes 2607 (19.2 %); Neutrophils 4023 (29.7 %); Platelets 2553 (18.8 %); NLR 4978 (36.7 %); PLR 3107 (22.9 %)
  2. IQR interquartile range, HBV hepatitis B virus, HCV hepatitis C virus, ART antiretroviral therapy, NLR neutrophil to lymphocytes ratio, PLR platelets to lymphocytes ratio